HIV Prevention in Pregnancy: The Emerging Role of LAI Cabotegravir + Rilpivirine
For women living with HIV, pregnancy represents both a profound joy and a critical moment for medical intervention. While antiretroviral therapy (ART) has dramatically reduced vertical transmission rates, new long-acting injectable formulations—like cabotegravir (CAB) and rilpivirine (RPV)—are reshaping treatment landscapes. But how do these innovations interact with pregnancy? And what do they mean for preventing mother-to-child transmission?
Current guidelines emphasize the importance of maintaining undetectable viral loads during pregnancy to prevent transmission. Yet emerging research suggests long-acting injectables (LAIs) may offer unique advantages—particularly for women who struggle with daily oral medications. Here’s what the latest evidence tells us about LAI CAB + RPV and its potential role in HIV prevention during pregnancy.
Understanding the Science: How LAI CAB + RPV Works
What Are Long-Acting Injectables (LAIs)?
LAIs are antiretroviral drugs delivered via intramuscular injection, providing sustained viral suppression for monthly or bimonthly doses. Unlike oral medications, they bypass gastrointestinal absorption issues and reduce the risk of missed doses.
LAI CAB + RPV vs. Oral ART
| Feature | LAI CAB + RPV | Oral ART (e.g., dolutegravir) |
|---|---|---|
| Administration | Monthly or bimonthly injections | Daily oral tablets |
| Adherence Barrier | Lower (fewer doses) | Higher (daily compliance critical) |
| Viral Load Stability | Consistent suppression between doses | Depends on strict adherence |
| Pregnancy Data | Limited but promising (ongoing studies) | Extensive safety profile established |
Why Viral Suppression Matters During Pregnancy
Research confirms that maintaining an undetectable viral load (<40 copies/mL) throughout pregnancy reduces the risk of vertical transmission to <1% or lower[1]. However, adherence challenges—such as nausea, forgetfulness, or social stigma—can disrupt oral ART regimens. LAIs may address these barriers for some women.
“The goal isn’t just treatment—it’s prevention. For pregnant women, even brief lapses in viral suppression can have irreversible consequences.”
What the Research Says (So Far)
1. Safety and Efficacy in Pregnancy: A Growing Body of Work
While LAI CAB + RPV was approved in 2021 for non-pregnant adults, its use during pregnancy remains off-label due to limited data. Key studies underway include:
- IMPAACT P1115 (NCT03790158): A Phase 3 trial evaluating LAI CAB + RPV in pregnant women with HIV. Primary outcomes include viral suppression and maternal/infant safety[2].
- ANRS 12360 (EudraCT 2019-001539-37): Assessing LAI CAB + RPV in pregnant women in France and West Africa, with interim results expected in 2027[3].
2. Potential Advantages for Pregnant Women
Preliminary data suggest LAIs could benefit pregnant women by:
- Improving adherence: Monthly injections eliminate the need for daily pills, which may be particularly helpful for women experiencing pregnancy-related nausea or fatigue.
- Stabilizing viral loads: LAIs provide consistent drug levels, reducing fluctuations that can occur with oral regimens.
- Simplifying postpartum care: Continuing LAI therapy post-delivery may streamline transition back to routine HIV management.
3. Critical Unknowns and Cautions
Despite promise, several questions remain unanswered:
- Vertical transmission risk: No studies have yet demonstrated that LAI CAB + RPV reduces transmission risk compared to oral ART. Current evidence is extrapolated from non-pregnant populations.
- Drug transfer to fetus: Limited data exist on placental transfer of CAB or RPV, though animal studies show minimal fetal exposure[4].
- Long-term neurodevelopmental effects: Follow-up data on infant outcomes are pending.
Current WHO, and U.S. DHHS guidelines do not recommend LAI CAB + RPV as first-line therapy during pregnancy due to insufficient evidence. Oral ART remains the standard.
For Clinicians and Patients: What to Do Now
1. Shared Decision-Making: Weighing the Options
For women considering LAI CAB + RPV during pregnancy, a structured discussion should include:
- Adherence history: Have you struggled with daily oral medications?
- Viral load stability: Is your current regimen achieving undetectable levels?
- Access to care: Can you reliably attend monthly injections?
- Clinical trial access: Are you eligible for IMPAACT P1115 or similar studies?
2. Monitoring and Support
If a woman elects LAI therapy during pregnancy, close monitoring is essential:
- Quarterly viral load testing (more frequent if viral load is near detection threshold).
- Regular renal and hepatic function assessments (LAIs are metabolized differently than oral drugs).
- Psychosocial support to address potential injection-site reactions or stigma.
3. Postpartum Planning
Transitioning from pregnancy to postpartum care requires coordination:
- Confirm infant HIV status via PCR testing at birth, 2 weeks, and 1–2 months.
- Discuss breastfeeding safety (WHO recommends avoiding breastfeeding if viral load is detectable[5]).
- Re-evaluate LAI continuation based on maternal health and treatment goals.
Frequently Asked Questions
Q: Can LAI CAB + RPV replace oral ART for pregnant women?
A: Not yet. Current guidelines prioritize oral ART (e.g., dolutegravir) due to robust safety data. LAIs may be considered only in clinical trials or for women with demonstrated adherence challenges.
Q: Are there side effects specific to LAI use in pregnancy?
A: Common injection-site reactions (pain, redness) may occur, but no pregnancy-specific side effects have been reported. Monitoring for systemic reactions (e.g., hypersensitivity) is advised.
Q: Will my baby be protected if I switch to LAIs?
A: Yes, if viral suppression is maintained. The risk of transmission depends on viral load, not the drug class. However, switching regimens should be done under medical supervision to avoid treatment interruptions.
Q: How do I access LAI CAB + RPV for pregnancy?
A: Enrollment in clinical trials (e.g., IMPAACT P1115) is the primary pathway. Discuss with your HIV specialist or maternal-fetal medicine provider.
3 Critical Takeaways
- Oral ART remains the gold standard for HIV prevention during pregnancy, with extensive safety data.
- LAI CAB + RPV shows promise for improving adherence but is not yet recommended outside clinical trials.
- Shared decision-making is key: Individual circumstances (adherence, viral load, access to care) should guide therapy choices.
The Road Ahead: What to Watch For
Over the next 12–24 months, we can expect:
- Interim results from IMPAACT P1115 and ANRS 12360, clarifying safety and efficacy.
- Potential updates to WHO HIV guidelines if robust data emerge.
- Expansion of LAI access in resource-limited settings, where adherence barriers are most pronounced.
For now, the message is clear: Undetectable equals untransmittable. Whether through oral or injectable therapy, the priority remains achieving and sustaining viral suppression to protect mothers and babies.
Keep reading